Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Revolo Biotherapeutics

    Client Virtual Booth

    REVOLO BIOTHERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Revolo Biotherapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    900 Camp Street New Orleans, LA 70130
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://revolobio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/revolobiotherapeutics/
    Twitter
    Twitter
    https://twitter.com/revolobio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Revolo Receives ODD from the U.S. FDA for its First-in-Class Peptide
    Revolo Receives ODD from the U.S. FDA for its First-in-Class Peptide

    https://www.globenewswire.com/news-release/2024/01/30/2820010/0/en/Revolo-Biotherapeutics-Receives-Orphan-Drug-Designation-from-the-U-S-FDA-for-its-First-in-Class-Peptide-as-a-Potential-Treatment-for-Eosinophilic-Esophagitis.html

    GLOBENEWSWIRE
    30 Jan 2024
    Share Share
    Revolo Biotherapeutics Presents New Data on ˜1805 at Annual Conference
    Revolo Biotherapeutics Presents New Data on ˜1805 at Annual Conference

    https://www.globenewswire.com//news-release/2023/11/07/2775291/0/en/Revolo-Biotherapeutics-Presents-New-Data-on-1805-at-the-American-College-of-Rheumatology-Convergence-2023-Annual-Conference.html

    GLOBENEWSWIRE
    07 Nov 2023
    Share Share
    Revolo Biotherapeutics Announces Data from Study of˜1104 in Atopic Adults
    Revolo Biotherapeutics Announces Data from Study of˜1104 in Atopic Adults

    https://www.globenewswire.com//news-release/2023/10/25/2766427/0/en/Revolo-Biotherapeutics-Announces-Data-from-Study-of-1104-in-Atopic-Adults.html

    GLOBENEWSWIRE
    25 Oct 2023
    Share Share
    Revolo to Present Data from Phase 2a Trial of ˜1104 in Eosinophilic Esophagitis
    Revolo to Present Data from Phase 2a Trial of ˜1104 in Eosinophilic Esophagitis

    https://www.globenewswire.com//news-release/2023/10/17/2761433/0/en/Revolo-Biotherapeutics-to-Present-Data-from-Phase-2a-Clinical-Trial-of-1104-in-Eosinophilic-Esophagitis-at-ACG-2023.html

    GLOBENEWSWIRE
    17 Oct 2023
    Share Share
    Revolo Announces the Completion of Phase 1 Ascending Dose Trial of ˜1104
    Revolo Announces the Completion of Phase 1 Ascending Dose Trial of ˜1104

    https://www.globenewswire.com//news-release/2023/09/21/2747192/0/en/Revolo-Biotherapeutics-Announces-the-Completion-of-Phase-1-Multiple-Ascending-Dose-Clinical-Trial-of-1104.html

    GLOBENEWSWIRE
    21 Sep 2023
    Share Share
    Revolo Biotherapeutics to Host Virtual KOL Event on ˜1104
    Revolo Biotherapeutics to Host Virtual KOL Event on ˜1104

    https://www.globenewswire.com/news-release/2023/08/08/2720563/0/en/Revolo-Biotherapeutics-to-Host-Virtual-KOL-Event-on-1104-A-First-in-Class-Peptide-for-Eosinophilic-Esophagitis-EoE-and-Allergic-Disease.html

    GLOBENEWSWIRE
    08 Aug 2023
    Share Share
    Revolo Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with EoE
    Revolo Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with EoE

    https://www.globenewswire.com/news-release/2023/07/18/2706324/0/en/Revolo-Biotherapeutics-Announces-Additional-Data-from-Phase-2a-Trial-of-1104-in-Adults-with-Active-Eosinophilic-Esophagitis.html

    GLOBENEWSWIRE
    18 Jul 2023
    Share Share
    Revolo Biotherapeutics Presents New Data for ˜1805 in Inflammatory Bowel Disease
    Revolo Biotherapeutics Presents New Data for ˜1805 in Inflammatory Bowel Disease

    https://www.globenewswire.com/news-release/2023/06/05/2681918/0/en/Revolo-Biotherapeutics-Presents-New-Data-for-1805-in-Inflammatory-Bowel-Disease-and-Rheumatoid-Arthritis-at-the-5th-Treg-Directed-Therapies-Summit.html

    GLOBENEWSWIRE
    05 Jun 2023
    Share Share
    Revolo Biotherapeutics Presents New Preclinical Data for 1104 at the ATS
    Revolo Biotherapeutics Presents New Preclinical Data for 1104 at the ATS

    https://www.globenewswire.com/news-release/2023/05/22/2673274/0/en/Revolo-Biotherapeutics-Presents-New-Preclinical-Data-for-1104-in-Acute-Respiratory-Distress-Syndrome-Associated-With-Influenza-Infection-at-the-ATS-2023-International-Conference.html

    GLOBENEWSWIRE
    22 May 2023
    Share Share
    Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings
    Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings

    https://www.globenewswire.com/news-release/2023/05/10/2665499/0/en/Revolo-Biotherapeutics-Announces-Presentations-at-Upcoming-Medical-Meetings.html

    GLOBENEWSWIRE
    10 May 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search